United Kingdom· GB-APID-10093011000001101
Naglazyme 5mg/5ml solution for infusion vials
A galsulfase product containing galsulfase, registered in United Kingdom by BioMarin (U.K.) Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Galsulfase is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB08 (galsulfase), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Galsulfase · ATC A16AB08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Galsulfase
- Manufacturer
- BioMarin (U.K.) Ltd
- Country
- United Kingdom (GB)
- ATC code
- A16AB08
- ATC class
- Galsulfase
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 3
- gtin0368135020196
- gtin00368135020196
- gtin00368135027263
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Galsulfase in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNAGLAZYMEBioMarin International Limited, Dublin
- CanadaNAGLAZYMEBIOMARIN PHARMACEUTICAL INC.
- SwitzerlandNaglazyme, Konzentrat zur Herstellung einer InfusionslösungDRAC AG
- SpainNAGLAZYME 1 mg/ml CONCENTRADO PARA SOLUCION PARA PERFUSIONBiomarin International Limited
- FinlandNaglazymeBiomarin International Limited
- FranceNAGLAZYME 1 mg/ml, solution à diluer pour perfusionBIOMARIN INTERNATIONAL LIMITED (IRLANDE)
- IrelandNaglazyme 1 mg/ml concentrate for solution for infusionBioMarin International Limited
- IcelandNaglazymeBioMarin International Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Naglazyme
- Liechtenstein · Naglazyme
- Norway · Naglazyme
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cfe36b93-3477-4505-8fa7-24c752782c98 GET /v1/drugs/cfe36b93-3477-4505-8fa7-24c752782c98?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "10093011000001101",
"desc": "Naglazyme 5mg/5ml solution for infusion vials (BioMarin (U.K.) Ltd)",
"form": "Solution for infusion",
"vpid": "36061811000001100",
"source": "dmd",
"vtm_id": "776076004",
"strength": "1 mg",
"substance": "Galsulfase",
"ingredient": "Galsulfase",
"supplier_code": "10075811000001102"
}See everything about galsulfase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.